Skip to main content
Molecule ProfilePublished

Inactivated Influenza

Inactivated Influenza molecule page image

Inactivated influenza vaccine (IIV) is a preventive vaccine used to protect against seasonal influenza, a contagious respiratory illness caused by influenza A and B viruses. It contains influenza virus particles or viral antigens that have been inactivated, meaning they cannot cause influenza infection. The vaccine stimulates the immune system to produce antibodies against the influenza strains included in the seasonal formulation. These antibodies help reduce the risk of influenza infection and may decrease the severity of illness, complications, hospitalization, and mortality in vulnerable populations. Inactivated influenza vaccines are generally administered by intramuscular injection, usually into the deltoid muscle in older children and adults or the anterolateral thigh in infants and young children. Vaccine composition is updated periodically to reflect influenza viruses expected to circulate during the upcoming season. Depending on the formulation, vaccines may be produced using embryonated eggs or cell culture technology and may be available as standard-dose or enhanced formulations for specific age groups. Annual vaccination is recommended because influenza viruses undergo frequent antigenic changes and immunity from previous vaccination or infection may decline over time.

Linked Products

0

FAQs

7

References

2

Overview

Inactivated influenza vaccine (IIV) is a preventive vaccine used to protect against seasonal influenza, a contagious respiratory illness caused by influenza A and B viruses. It contains influenza virus particles or viral antigens that have been inactivated, meaning they cannot cause influenza infection. The vaccine stimulates the immune system to produce antibodies against the influenza strains included in the seasonal formulation. These antibodies help reduce the risk of influenza infection and may decrease the severity of illness, complications, hospitalization, and mortality in vulnerable populations. Inactivated influenza vaccines are generally administered by intramuscular injection, usually into the deltoid muscle in older children and adults or the anterolateral thigh in infants and young children. Vaccine composition is updated periodically to reflect influenza viruses expected to circulate during the upcoming season. Depending on the formulation, vaccines may be produced using embryonated eggs or cell culture technology and may be available as standard-dose or enhanced formulations for specific age groups. Annual vaccination is recommended because influenza viruses undergo frequent antigenic changes and immunity from previous vaccination or infection may decline over time.

Background and Date of Approval

Inactivated influenza vaccines have been used for decades as a primary public health measure for preventing seasonal influenza. The development of influenza vaccines began in the early twentieth century, with inactivated formulations subsequently becoming widely used for seasonal immunization. These vaccines are produced using influenza viruses grown in embryonated eggs or cell-based systems, followed by inactivation and purification of viral antigens. Regulatory authorities such as the U.S. Food and Drug Administration (FDA), European Medicines Agency (EMA), and national regulatory agencies, including India's Central Drugs Standard Control Organization (CDSCO), oversee vaccine quality, safety, efficacy, and manufacturing standards. Influenza vaccines undergo annual strain-selection and formulation updates based on global influenza surveillance data from the World Health Organization (WHO). Clinical studies supporting influenza vaccine approval and updates evaluate immunogenicity, safety, and, where applicable, clinical efficacy against circulating influenza strains. Individual influenza vaccine products have different regulatory approval histories, age indications, and formulation specifications.

Uses

Inactivated influenza vaccine is indicated for active immunization against influenza disease caused by influenza virus strains included in the vaccine formulation. Seasonal vaccination is recommended for eligible individuals, particularly children, older adults, pregnant women, healthcare workers, and people with chronic medical conditions or weakened immune systems who are at increased risk of influenza-related complications. Depending on the specific product, inactivated influenza vaccines may be approved for use in individuals aged six months and older. Vaccination is primarily intended to prevent seasonal influenza and reduce the risk of severe disease, pneumonia, hospitalization, and influenza-associated complications. It is administered as a preventive vaccine rather than as treatment for an active influenza infection. Inactivated influenza vaccines may be used as standalone immunization and can generally be administered alongside other recommended vaccines according to applicable vaccination guidelines.

Administration

Inactivated influenza vaccines are generally administered by intramuscular injection, preferably into the deltoid muscle in adults and older children, or the anterolateral thigh in infants and younger children. The standard dose for many formulations is 0.5 mL, although age-specific formulations and dosing volumes may differ depending on the product and national recommendations. Children aged six months through eight years who have not received the required previous influenza vaccine doses may need two doses administered at least four weeks apart during their first vaccination season. Previously vaccinated children and most adults generally require one dose per influenza season. Vaccination is recommended annually because circulating influenza strains change and vaccine-induced immunity may decline over time. The timing of administration should follow local seasonal influenza recommendations and product-specific prescribing information.

Side Effects

Common side effects of inactivated influenza vaccine are generally mild and temporary. These may include pain, redness, swelling, or tenderness at the injection site, headache, fatigue, muscle aches, mild fever, and occasionally nausea or general discomfort. Some individuals may experience reduced appetite or irritability, particularly young children. These reactions usually resolve within a few days without specific treatment. Local injection-site reactions are among the most frequently reported adverse effects. The vaccine does not cause influenza because it contains inactivated virus or viral antigens that cannot produce an active influenza infection. Side effects may vary depending on the vaccine formulation, age of the recipient, and individual immune response.

Warnings

Serious adverse events following inactivated influenza vaccination are uncommon but may include severe allergic reactions such as anaphylaxis. Vaccination should not be administered to individuals with a history of severe allergic reaction to a previous dose of the specific vaccine or to a component of the formulation, unless an appropriate specialist assessment and alternative vaccination strategy are undertaken. Guillain-Barré syndrome has been reported rarely following influenza vaccination, and a history of Guillain-Barré syndrome occurring within six weeks of a previous influenza vaccine dose is considered a precaution. Syncope may occur following vaccination, particularly in adolescents and young adults, and appropriate observation and preventive measures should be considered. Some formulations may have additional product-specific warnings, including febrile seizures in certain pediatric populations. Vaccination should be deferred in individuals with moderate or severe acute illness until recovery, unless the healthcare professional determines otherwise. Severe reactions require immediate medical evaluation and appropriate management.

Precautions

Before administering inactivated influenza vaccine, healthcare professionals should review the individual's vaccination history, previous allergic reactions, current illness, and relevant medical conditions. Individuals with a history of Guillain-Barré syndrome within six weeks of a previous influenza vaccine should undergo an individualized risk-benefit assessment. Egg allergy is not generally a reason to avoid influenza vaccination under current recommendations in many countries, although product-specific guidance should be followed. Inactivated influenza vaccines are generally suitable for pregnant women and immunocompromised individuals when indicated, as they do not contain live replicating influenza virus. Classic drug interactions are uncommon, although immunosuppressive therapies may reduce the immune response to vaccination. Anticoagulant therapy or bleeding disorders may require appropriate precautions during intramuscular administration. Vaccine administration should be coordinated with other recommended immunizations according to local guidelines.

Expert Tips

Healthcare professionals should verify the age indication, formulation, seasonal composition, dose, and vaccination history before administration. Ensure that the vaccine is stored under recommended refrigerated conditions, generally between 2°C and 8°C, and protected from freezing. Inspect the vaccine before use and follow manufacturer-specific instructions regarding preparation and administration. Use the appropriate injection site and needle length according to the recipient's age, body size, and clinical circumstances. Counsel patients that protection generally develops over approximately two weeks and that annual vaccination is necessary to maintain protection against changing influenza strains. Explain common local and systemic reactions and advise patients to seek immediate medical attention for signs of a severe allergic reaction. Document the vaccine name, manufacturer, lot number, expiry date, dose, administration date, and injection site. Vaccination programs should prioritize individuals at increased risk of influenza complications and follow current national and seasonal recommendations.

FAQs

What is Inactivated Influenza Vaccine?

Inactivated influenza vaccine is a preventive vaccine containing killed influenza viruses or viral antigens that stimulate immunity against seasonal influenza. It helps reduce the risk of influenza infection and its complications.

How is Inactivated Influenza Vaccine administered?

It is generally administered by intramuscular injection into the deltoid muscle in adults and older children or the anterolateral thigh in infants and young children. The dose and schedule depend on age, vaccine formulation, and previous vaccination history.

What conditions is Inactivated Influenza Vaccine used for?

It is used to prevent seasonal influenza caused by influenza A and B virus strains included in the vaccine. It is particularly recommended for individuals at increased risk of influenza-related complications.

What are common side effects?

Common side effects include injection-site pain, redness, swelling, mild fever, headache, fatigue, and muscle aches. These reactions are usually temporary and resolve within a few days.

What serious risks should be monitored?

Serious allergic reactions, including anaphylaxis, are rare but require immediate medical attention. Guillain-Barré syndrome has been reported rarely, and individuals with a history of this condition following influenza vaccination require careful assessment.

How long is treatment continued?

Influenza vaccination is preventive rather than therapeutic and is generally administered once every influenza season. Some children may require two doses during their first vaccination season, depending on their vaccination history and applicable guidelines.

What monitoring is required during treatment?

Recipients should be monitored for immediate allergic reactions following vaccination, with observation according to local clinical protocols. Healthcare professionals should review vaccination history, assess relevant precautions, and document vaccine administration and any adverse reactions.

References

  1. https://pmc.ncbi.nlm.nih.gov/articles/PMC2643340/
  2. https://go.drugbank.com/categories/DBCAT003997

More Molecule Profiles

Browse other published molecule pages in the catalog.

Durvalumab

Durvalumab is a human monoclonal antibody belonging to the immune checkpoint inhibitor class of anticancer medicines. It specific…

View molecule page

Dulaglutide

Dulaglutide is a long-acting glucagon-like peptide-1 (GLP-1) receptor agonist used to improve blood glucose control in people wit…

View molecule page

CYTOKINE REMOVAL

Cytokine removal is an extracorporeal blood-purification approach intended to reduce excessive concentrations of circulating cyto…

View molecule page